GlassScriptPhysician profile
Robert Adam Cambridge
NPI 1386699072
$7,889.14
in general payments reported to CMS, 2019-2025
37 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $557 · 2021: $647 · 2022: $1,142 · 2023: $1,912 · 2024: $1,497 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,645.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,721.84 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $894.34 | 2023-2025 | |
| Argenx US, INC. | $739.09 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $591.93 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Novartis Pharmaceuticals Corporation | $525.62 | 2019-2025 | |
| Tanabe Pharma America, INC. | $375.04 | 2022-2025 | Radicava |
| Amgen INC. | $350.80 | 2019-2025 | Uplizna |
| Supernus Pharmaceuticals, INC. | $272.13 | 2019-2020 | |
| Eisai INC. | $263.01 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $202.97 | 2020-2023 | Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $199.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $177.79 | 2021 | |
| Mallinckrodt Hospital Products INC. | $169.67 | 2022-2025 | Acthar |
| Allergan, INC. | $140.90 | 2019-2021 | |
| Horizon Therapeutics Plc | $133.69 | 2022-2023 | Uplizna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $129.76 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.54 | 2019 | |
| Ucb, INC. | $88.80 | 2023-2025 | Rystiggo, Briviact |
| Harmony Biosciences LLC | $80.35 | 2020 | |
| Biogen, INC. | $78.75 | 2021-2023 | Tysabri |
| Alexion Pharmaceuticals, INC. | $77.34 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $66.48 | 2019 | |
| Upsher-Smith Laboratories LLC | $64.46 | 2020-2021 | |
| Mdd US Operations, LLC | $61.18 | 2020 | |
| Abbott Laboratories | $47.28 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Livanova USA, INC. | $46.16 | 2019-2020 | |
| Lundbeck LLC | $42.17 | 2022-2025 | Vyepti |
| Kyowa Kirin, INC. | $29.94 | 2024 | Nourianz |
| Ani Pharmaceuticals, INC. | $28.26 | 2024 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $26.82 | 2024 | Nuplazid |
| Axsome Therapeutics, INC. | $26.18 | 2025 | Symbravo |
| Neurocrine Biosciences, INC. | $25.77 | 2019 | |
| Sk Life Science, INC. | $23.14 | 2020 | |
| Boston Scientific Corporation | $20.31 | 2023 | |
| Amneal Pharmaceuticals LLC | $16.63 | 2024 | Ongentys |
| Ceribell, INC. | $16.35 | 2023 | Ceriibell Rapid Response Eeg |
| Bausch Health US, LLC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cambridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.